Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target By Investing.com
Stifel has reiterated its Buy rating on Inhibrx Biosciences (NASDAQ: INBX) with a $325.00 price target, noting a substantial upside from the current price. The firm's positive outlook is based on upcoming randomized durability data for INBRX-106, strong management insights into the drug's mechanism, and recent financial and regulatory progress including an expanded credit facility and the FDA's acceptance of ozekibart's Biologics License Application. Despite a significant 310% return over the past year, InvestingPro data suggests the shares may be overvalued.
Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target By Investing.com
Stifel maintained its Buy rating on Inhibrx Biosciences (NASDAQ: INBX) with a $325.00 price target, despite the stock's significant 310% return over the past year and potential overvaluation. The firm anticipates strong potential ahead of randomized durability data for INBRX-106 next month and noted Inhibrx's recent credit facility expansion and FDA acceptance of its Biologics License Application for ozekibart, a potential first-in-class treatment for chondrosarcoma.
Western Standard LLC Takes $4.45 Million Position in Inhibrx Biosciences, Inc. $INBX
Western Standard LLC has acquired a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX), purchasing 47,000 shares valued at approximately $4.45 million, making it the fund's 19th largest holding. Despite this institutional interest, analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $150. Inhibrx Biosciences recently reported a quarterly loss of $2.34 per share, missing consensus estimates.
Inhibrx Biosciences (NASDAQ:INBX) Downgraded to Strong Sell Rating by Wall Street Zen
Wall Street Zen has downgraded Inhibrx Biosciences (NASDAQ:INBX) to a "strong sell" rating, despite a mixed outlook from other analysts, with the overall consensus remaining "Hold" and an average price target of $150. The company's shares opened at $88.37, significantly below its 12-month high, and it recently reported a quarterly loss that missed analyst expectations. Institutional investors hold a substantial stake in the company, with firms like Morgan Stanley and BlackRock among its major shareholders.
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors?
Inhibrx Biosciences (INBX) reported widening net losses in Q2 2026, but also achieved significant clinical milestones including FDA acceptance of ozekibart's BLA for chondrosarcoma with a PDUFA date of April 14, 2027. The company is also anticipating Phase 2 data for INBRX-106 in head and neck squamous cell carcinoma. While these developments sharpen the investment narrative by providing clear catalysts, investors are reminded that the company's story still relies on capital access and execution, with a financing-related risk highlighted.
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors?
Inhibrx Biosciences reported widening net losses in Q2 2026, alongside key clinical milestones including FDA acceptance of ozekibart's biologics license application with a PDUFA goal date of April 14, 2027, and upcoming Phase 2 data for INBRX-106. While these regulatory and clinical advancements are significant, the company's financial results and reliance on capital emphasize the ongoing risk-reward balance for investors. The article suggests that despite these milestones, the stock price might be too optimistic, urging investors to conduct thorough research.
Trading the Move, Not the Narrative: (INBX) Edition
This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.
Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of warrants being subject to a 9.99% beneficial ownership limitation. The filing emphasizes the shared voting and dispositive power over these shares among the reporting group.
Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing
Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole voting and dispositive power over these shares, which are held on behalf of its clients.
Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss
Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating and a price target of $150.00, while institutional investors hold a significant 82.46% stake in the company.
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages
Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired a new position worth approximately $78.3 million in the second quarter.
Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS
Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's stock.
Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com
This article reports on Inhibrx Biosciences Inc.'s Form 8K filing for August 13. The company's stock symbol INBX is mentioned with a performance of -8.91%. The content primarily serves as a placeholder or brief announcement from Investing.com.
Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com
This article reports on the filing of a Form 8K by Inhibrx Biosciences Inc. for August 13. The brief notice highlights the company's regulatory submission without providing further details on its content. It includes the stock symbol INBX, which saw a slight decrease.
FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart
Inhibrx reported a net loss of $36.7 million in Q2 2026, with R&D expenses at $23.9 million and G&A at $8.3 million. The company secured an amended loan with Oxford Finance for up to $325.0 million, with $100.0 million already funded. The FDA accepted Inhibrx's BLA for ozekibart (INBRX-109) for conventional chondrosarcoma, setting an April 14, 2027 PDUFA goal date, and the company initiated new Phase 1 colorectal cancer cohorts for ozekibart.
Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data
Inhibrx Biosciences (INBX) reported a net loss of $70.1 million for the first half of 2026, with no revenue, while holding $133.3 million in cash and equivalents. Despite the losses, the company advanced its clinical pipeline, with ozekibart achieving a statistically significant progression-free survival benefit in chondrosarcoma and its biologics license application accepted by the FDA. Additionally, INBRX-106 showed positive interim Phase 2 HexAgon data in head and neck cancer, supporting further late-stage development.
Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold"
Wall Street Zen has upgraded Inhibrx Biosciences (NASDAQ:INBX) from a "Sell" to a "Hold" rating, bringing the consensus rating for the stock to "Hold" with an average price target of $150. This upgrade comes despite the company reporting a quarterly loss of $2.15 per share, which was worse than analysts' expectations. Institutional ownership in INBX is substantial, with major investors like BlackRock and Morgan Stanley increasing their positions.
Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday
Inhibrx Biosciences (INBX) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 12th. Analysts predict a loss of $2.28 per share, following a previous quarter where the company missed expectations with a $2.15 per share loss. The stock, which has seen significant volatility, currently holds an average "Hold" rating from analysts with a target price of $150.
(INBX) Volatility Zones as Tactical Triggers
This article analyzes Inhibrx Biosciences Inc Com (NASDAQ: INBX), highlighting positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. It identifies elevated downside risk and provides AI-generated institutional trading strategies for different risk profiles. The analysis includes position trading, momentum breakout, and risk hedging strategies, alongside multi-timeframe signal analysis with support and resistance levels.
Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America
Bank of America Corporation has reported a beneficial ownership of 857,318 shares of Inhibrx Biosciences (INBX) common stock, which represents 5.9% of the class. This ownership is held through various affiliated entities, including BofA Securities, Inc., Bank of America, N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware. The filing indicates shared voting power over 857,306 shares and shared dispositive power over 857,318 shares, with no sole voting or dispositive power.
Inhibrx Biosciences Inc (INBX) Institutional Confidence
The article analyzes the institutional confidence score for Inhibrx Biosciences Inc (INBX), which currently stands at 7.00, placing it 80th in its industry. Institutional shareholding has increased to 84.51%, with Andreas Halvorsen being the largest shareholder. The report also lists other significant institutional shareholders and their recent activity.
Inhibrx Biosciences (INBX) Expands Its Credit Facility, Is The Valuation Risk Priced In?
Inhibrx Biosciences (INBX) recently expanded its credit facility to $500 million, leading to a reassessment of its valuation by investors, despite a strong year-to-date return. The company's high price-to-book ratio of 55.6x, compared to an industry average of 2.4x, reflects its negative equity and reliance on external borrowing. This situation highlights significant financing and balance sheet risks that investors need to consider carefully.
Inhibrx Biosciences Market Sentiment
The article provides a market sentiment overview for Inhibrx Biosciences (INBX), detailing analyst consensus, short interest, and recent analyst actions. Key signals indicate a "Buy" consensus from analysts with a significant upside on the price target, alongside a high short interest percentage. The analyst actions section lists various ratings and price target changes from firms like Stifel and JMP Securities.
INBX|Inhibrx Biosciences Inc|Price:82.350|Chg%:+0.800
This article provides a comprehensive stock analysis of Inhibrx Biosciences Inc (INBX), highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. Despite a predicted medium-term downtrend, multiple analysts rate it as "Buy" with a high price target, suggesting strong long-term prospects. The company is in a growing phase, though it has experienced a turnaround to a loss, and shows high institutional ownership.
Inhibrx Biosciences, Inc. $INBX Shares Bought by SummitTX Capital L.P.
SummitTX Capital L.P. significantly increased its stake in Inhibrx Biosciences (NASDAQ:INBX) by 66.3% during the first quarter, now owning 137,821 shares valued at approximately $9.3 million. Other institutional investors also adjusted their holdings, with institutional investors and hedge funds collectively owning 82.46% of the stock. Inhibrx Biosciences reported a quarterly loss of $2.15 per share, missing consensus estimates, and analysts have a mixed sentiment on the stock, which carries an average "Hold" rating and a price target of $150.
Inhibrx Biosciences Inc (INBX) Cash Flow
This article provides a comprehensive overview of Inhibrx Biosciences Inc's (INBX) cash flow statement, breaking down quarterly and annual data for operating, investing, and financing activities. It features detailed financial figures for various cash flow components, including net income, capital expenditures, and changes in working capital, presented in a tabular format. Additionally, the article includes a FAQ section defining key cash flow terms and highligting INBX's performance in these areas, such as its fiscal 2025 operating cash flow and capital expenditures in the latest quarter.
Inhibrx Biosciences, Inc. Revenue Breakdown – NASDAQ:INBX
Inhibrx Biosciences, Inc. (NASDAQ: INBX) generated $1.30 million USD in revenue last year, primarily from its Biologic Therapeutic segment. This represents a significant increase from the previous year's $200,000 USD. The United States was the company's largest contributor to revenue.
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides details on the revenue breakdown for Inhibrx Biosciences Inc (INBX). It indicates that relevant data for business segments and regional revenue contribution have not yet been disclosed by the company, though it does list a United States revenue figure of $1.30 million. The report also includes basic stock information such as market cap and recent price changes.
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Inhibrx Biosciences Inc (INBX), listing major shareholders and their respective proportions. It also presents institutional shareholding trends over several quarters and highlights shareholder activity, including changes in holdings for key investors. Additionally, the article includes a section on related ETFs with INBX Proportion.
INBX|Inhibrx Biosciences Inc|Price:81.550|Chg%:-3.450
This article provides a detailed financial overview of Inhibrx Biosciences Inc (INBX), including its stock performance, market capitalization, and various financial statements. It highlights the company's latest earnings, revenue, EPS, and analyst ratings, offering a comprehensive look at its financial health and historical performance through quarterly and annual data. The article also includes an FAQ section addressing key financial metrics based on the FY2025 earnings report.
INBX|Inhibrx Biosciences Inc|Price:81.550|Chg%:-3.450
Inhibrx Biosciences Inc (INBX) closed at $81.550, down 4.06%, on July 24, 2026. The company is a clinical-stage biopharmaceutical firm developing novel biologic therapeutic candidates, including ozekibart (INBRX-109) and INBRX-106. Key executives and shareholders are listed, with 258 institutions holding shares as of Q1 2026.
Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile?
Inhibrx Biosciences expanded its credit facility to $500.0 million with Oxford Finance, including an immediate $100.0 million Term C Loan. This move reduces short-term financing pressure and offers management more flexibility for trials, but also introduces higher leverage and financial risk. The company's investment narrative hinges on its oncology and immunotherapy pipeline, with key catalysts including the ozekibart BLA review and planned HexAgon Phase 3 start.
Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million
Inhibrx Biosciences has expanded its loan facility with Oxford Finance to $500 million through a second amendment to their agreement. This expansion includes a new tranche of up to $325 million, with $100 million funded immediately as a Term C Loan and an additional $225 million available as a Term D Loan. Prior to this amendment, the company had already drawn $175 million from the facility.
Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants
Inhibrx Biosciences expanded its senior secured credit facility with Oxford Finance and other lenders to up to $500 million, immediately drawing $100 million. The company also issued warrants for 21,457 shares to the lenders and pledged its equity in Poplar Therapeutics as collateral. These actions aim to enhance liquidity and strategic flexibility for ongoing development programs.
Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit
Inhibrx Biosciences has significantly expanded its credit facility with Oxford Finance to an aggregate principal amount of up to $500 million, including an immediate $100 million Term C Loan and potential additional Term D Loans of $225 million. This expansion is outlined in an 8-K filing and includes the issuance of warrants to lenders. The biopharmaceutical company plans to use these funds to maintain momentum in advancing its therapeutic programs, ozekibart (INBRX-109) and INBRX-106, particularly as it anticipates upcoming data readouts.
Press Release: Inhibrx Announces Amended Loan Agreement With Oxford Finance, Expanding Total Facility to $500.0 Million
Inhibrx has announced an amended loan agreement with Oxford Finance, increasing its total debt facility from $200.0 million to $500.0 million. This expanded financing is expected to provide greater financial flexibility as Inhibrx approaches potential commercialization for its drug candidates. The agreement also adjusts milestones and extends interest-only payments.
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
Inhibrx Biosciences, Inc. (Nasdaq: INBX) has expanded its loan agreement with Oxford Finance LLC, increasing the total credit facility to $500.0 million. This amendment provides an additional tranche of up to $325.0 million, with $100.0 million funded immediately and an option for an additional $225.0 million. The company issued warrants to Oxford Finance as part of the deal, and the funds will support the advancement of its clinical pipeline, particularly ozekibart (INBRX-109) and INBRX-106.
Price-Driven Insight from (INBX) for Rule-Based Strategy
Inhibrx Biosciences Inc (NASDAQ: INBX) is showing strong sentiment across all horizons, supporting an overweight bias. AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis highlights an exceptional 98.5:1 risk-reward setup targeting a 28.4% gain versus 0.3% risk, with strong signals across near-term, mid-term, and long-term timeframes.
Inhibrx Biosciences (INBX) Stock Analysis Report | Financials & Insights
This report provides a stock analysis for Inhibrx Biosciences (INBX), a clinical-stage biopharmaceutical company. It details the company's general information, current stock performance, and a methodology for grading the stock based on various financial metrics. The analysis highlights INBX's strong momentum and above-average Sharpe ratio, indicating good risk-adjusted returns over the past five years.
How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors
Inhibrx Biosciences (INBX) was reclassified from Russell value/defensive indices to growth/small-cap indices in late June 2026. This shift primarily affects the type of investors holding the stock and doesn't change the underlying business catalysts, which include regulatory progress, clinical trial execution, and balance sheet management. Investors should note the company's ongoing losses and negative equity, and some estimates suggest the stock may be trading beyond its fair value.
How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors
Inhibrx Biosciences (INBX) has been reclassified from Russell value and defensive indices to growth and small-cap benchmarks in late June 2026. This shift primarily affects the investor base rather than the core business drivers, with key catalysts remaining FDA decisions, clinical trial execution, and balance sheet management. The article suggests that despite the reclassification, the company is still early in its commercialization phase, faces ongoing losses, and might be trading beyond its estimated fair value.
(INBX) Price Dynamics and Execution-Aware Positioning
This article analyzes Inhibrx Biosciences Inc (NASDAQ: INBX) price dynamics, identifying a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional 97.2:1 risk-reward setup, targeting a substantial gain with minimal risk. The analysis provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide potential trades.
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index
Inhibrx Biosciences, Inc. (NasdaqGS: INBX) has been removed from the Russell 2000 Defensive Index. This change is part of broader index adjustments, as the company was also added to other Russell indices like the Russell 2500 Growth and Russell 2000 Growth Benchmarks around the same date. The biopharmaceutical company is actively developing novel biologic therapeutic candidates, including ozekibart and INBRX-106.
Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In?
Inhibrx Biosciences (INBX) received FDA acceptance for its Biologics License Application for ozekibart, following positive Phase III data. Despite significant past share price momentum and an analyst target considerably higher than the current trading price, the company's financials show it is still a clinical-stage business with negative shareholders' equity and high-risk funding. Investors are cautioned to weigh the potential rewards against the inherent risks, including ongoing clinical development and financial vulnerabilities.
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark
Inhibrx Biosciences, Inc. (NasdaqGS: INBX) has been added to the Russell 3000E Growth Benchmark. This pharmaceutical company, which specializes in developing novel biologic therapeutic candidates, is actively advancing its clinical pipeline, including therapies like ozekibart (INBRX-109) and INBRX-106. The inclusion in this benchmark index highlights the company's growth trajectory and market recognition.
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) dropped from Russell 2000 Value-Defensive Index
Inhibrx Biosciences, Inc. (NasdaqGS:INBX) has been removed from the Russell 2000 Value-Defensive Index. This change is part of broader Russell index reconfigurations, which also saw the company dropped from other defensive/value benchmarks and added to growth benchmarks like the Russell 2500 Growth and Russell 3000 Growth. Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates.
Enterprise value to revenue forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX
This article provides a financial snippet for Inhibrx Biosciences, Inc. (NASDAQ: INBX), focusing on its enterprise value to revenue forward metric. It details that the market is currently closed with no trades recorded for the company. The content appears to be a stub or a brief financial data point from a larger platform.
Price to sales forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX
This article provides financial data, specifically the "Price to sales forward" for Inhibrx Biosciences, Inc. (NASDAQ: INBX). It notes that the market is closed with no trades recorded at the time of publication and lists the company on the Nasdaq Stock Market. The content is primarily a data point and lacks further narrative or analysis.
Inhibrx Biosciences (INBX) Short Interest & Short Float | Updated Jun 2026
Inhibrx Biosciences (INBX) reported a short interest of 3.30 million shares as of June 15, 2026, representing 27.52% of its public float, an increase of 3.79% from the previous report. The short interest ratio is 10.3 days to cover, indicating significant pessimism towards the stock. This report details the historical short interest data for INBX and defines key metrics like short interest, short float, and days to cover, comparing INBX's figures to competitors in the pharmaceutical sector.
INBX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Inhibrx Biosciences, Inc. (INBX) stock, including analyst price targets, past performance, and basic financial information. It notes that analysts have a maximum estimate of $325.00 and a minimum estimate of $230.00 for INBX's future price. The stock has experienced a significant increase of 552.36% over the last year, despite recent weekly and monthly declines.
